⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Regenicin, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Regenicin, Inc.
↗Las Vegas, NV, USA
Regenicin, Inc. is a biotechnology company focused on the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs. The company's primary product candidate, NovaDerm, is a tissue-engineered living skin substitute prepared from a patient's own (autologous) skin cells, designed for the treatment of severe burns and chronic wounds.
Founded in 2007 (formerly Windstar, Inc.), the company is a publicly traded entity listed on the OTC Markets. Despite its long history, the company has maintained a very small operational footprint and has faced significant challenges in bringing its lead product to market, with limited financial activity and minimal reported revenue in recent years.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M
Founded:2007
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
STOCK
Exchange:OTCPK
Ticker:RGIN
Market Cap:$0.000015M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Cell therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Supply agreement for closed herd collagen (2016)
COMPETITION
Position:Niche Player
Competitors:Avita Medical, Enlivex Pharmaceuticals, Sernova, Emmaus Medical, Kerecis
LEADERSHIP
Key Executives:
Randy McCoy - CEO
LINKS
Website:regenicin.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Regenicin, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.